Anti-nampt antibodies and uses thereof
AssigneeAqualung Therapeutics
InventorsJOE G.N. GARCIA, DARRAGH MACCANN
Life of this patent
Estimating the term…
Abstract
Anti-nicotinamide phosphoribosyltransferase (NAMPT) antibodies, or antigen binding fragments thereof, are described, as well as methods for treating a subject having a (NAMPT)-associated local and/or systemic inflammatory disorder.
Claims27
A method of treating a subject having Coronavirus disease 2019 (COVID-19), the method comprising administering to the subject an effective amount of an isolated antibody, or an antigen-binding fragment thereof, that binds to human nicotinamide phosphoribosyltransferase (NAMPT).
An isolated antibody, or an antigen-binding fragment thereof, that binds to human NAMPT, said antibody or antigen-binding fragment thereof comprising:
- (i) a heavy chain variable region comprising a CDR1 domain having an amino acid sequence as set forth in SEQ ID NO:
- 3;
- a CDR2 domain having an amino acid sequence as set forth in SEQ ID NOs:
- 4 or 29;
- and a CDR3 domain having an amino acid sequence as set forth in SEQ ID NO:
- 5;
- and
- (ii) a light chain variable region comprising a CDR1 domain having an amino acid sequence as set forth in SEQ ID NO:
- 6 or 11;
- a CDR2 domain having an amino acid sequence as set forth in SEQ ID NO:
- 7, 12, 14, 33, 35 or 37;
- and a CDR3 domain having an amino acid sequence as set forth in SEQ ID NO:
- 8.
Dependencies are inferred from the claim text.